Core Viewpoint - Shandong Weiming Pharmaceutical Co., Ltd. is facing significant operational challenges due to regulatory actions against its subsidiary Tianjin Weiming, which has been suspended from production and sales, impacting the company's revenue heavily [1][3][5]. Group 1: Regulatory Actions - Tianjin Weiming was subjected to production and sales suspension by the Tianjin Drug Administration due to non-compliance with Good Manufacturing Practice (GMP) standards [3]. - The core product, human interferon α2b spray, has faced procurement suspensions from Inner Mongolia and Tibet due to unsatisfactory inspection results [2][3]. - The company has previously experienced similar issues, with the Jiangxi Provincial Procurement Office announcing that the interferon α2b spray did not meet biological activity standards [4][8]. Group 2: Financial Impact - In 2024, Tianjin Weiming is projected to generate revenue of 217 million yuan, accounting for 60.09% of Weiming Pharmaceutical's total revenue [3][6]. - The recall of the interferon α2b spray has already reduced the company's revenue by 23.17 million yuan in 2024, with further implications for 2025 sales [5]. - Weiming Pharmaceutical has reported continuous losses for three consecutive years, with a record loss of 332 million yuan in 2023 [6][8]. Group 3: Product and Market Dynamics - The interferon product line is crucial for Weiming Pharmaceutical, contributing significantly to its revenue, with a gross margin of 79.92% in 2024 [7]. - The company has been involved in a competitive procurement process for interferon products, with the interferon α2b spray being the only product to win a bid at a price of 33.58 yuan for a specific volume [8]. - The procurement process, known as "small country procurement," has introduced uncertainties regarding the future of the company's core products due to the recent regulatory issues [8][9]. Group 4: Stock Market Reaction - Following the announcement of the production suspension, Weiming Pharmaceutical's stock fell to a limit down, closing at 6.68 yuan per share, with a total market capitalization of 4.407 billion yuan [10].

证券代码：002581 证券简称：未名医药 公告编号：2025-025 山东未名生物医药股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2024年度股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性：公司2024年度股东大会会议的召集、召开符 合《公司法》等法律、法规、规范性文件和《公司章程》的有关规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2025年5月19日下午2:30 （2）网络投票时间： ①通过深圳证券交易所交易系统进行投票的时间：2025年5月19日上午 9:15-9:25，9:30-11:30，下午1:00-3:00； ②通过互联网投票系统进行网络投票的时间：2025年5月19日9:15-15:00。 5、会议的召开方式：本次股东大会采用现场表决与网络投票相结合的方式 召开。 6、会议的股权登记日：2025年5月14日 7、出席对象： | 提案编码 | 提案名称 | 备注 | | --- | --- | --- | ...

证券代码：002581 证券简称：未名医药 公告编号：2025-027 山东未名生物医药股份有限公司(以下简称"公司")第五届监事会第二十三 次会议于 2025 年 4 月 28 日上午 11 时以通讯方式召开。应参加表决监事 3 名， 实际参加表决监事 3 人，分别为：柯莹、闫雪明、彭龙。监事会会议通知已于 2025 年 4 月 25 日以通讯方式发出，会议由公司监事主席柯莹女士主持。本次监事会 的召集和召开符合国家有关法律、法规、《监事会议事规则》及《公司章程》的 规定。本次会议逐项审议了如下议案： 二、监事会会议审议情况 山东未名生物医药股份有限公司 第五届监事会第二十三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 （一）审议通过了《2025 年第一季度报告》 本次注销事项在公司 2023 年第一次临时股东大会决议对董事会的授权范围 内，已经公司第五届董事会薪酬与考核委员会第九次会议审议通过，无需提交股 东大会审议。具体内容详见同日在巨潮资讯网（www.cninfo.com.cn）上披露的 《关于 2023 年 ...

证券代码：002581 证券简称：未名医药 公告编号：2025-026 山东未名生物医药股份有限公司 第五届董事会第三十六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东未名生物医药股份有限公司(以下简称"公司")第五届董事会第三十六 次会议于 2025 年 4 月 28 日上午 10 时以通讯方式召开。应参加表决董事 11 名， 实际参加表决董事 11 人，分别为：岳家霖、刘文俊、黄桂源、岳莹、于秀媛、 于文杰、蔡艳红、张荣富、刘洋、夏阳、赵辉。董事会会议通知已于 2025 年 4 月 25 日以通讯方式发出，会议由公司董事长岳家霖先生主持。本次董事会的召集 和召开符合国家有关法律、法规、《董事会议事规则》及《公司章程》的规定。 本次会议逐项审议了如下议案： 二、董事会会议审议情况 （一）审议通过了《2025 年第一季度报告》 具体内容详见同日在巨潮资讯网（www.cninfo.com.cn）上披露的《2025 年第 一季度报告》。 表决情况：同意 11 票,反对 0 票,弃权 0 票。 表决结果：通过。 （二） ...

山东未名生物医药股份有限公司 监事会关于公司 2023 年股票期权激励计划第二个行权期行 权条件未成就及注销部分股票期权的核查意见 山东未名生物医药股份有限公司（以下简称"公司"）监事会根据《中华人 民共和国公司法》《中华人民共和国证券法》《上市公司股权激励管理办法》《深 圳证券交易所上市公司自律监管指南第 1 号——业务办理》等有关法律、法规和 规范性文件以及《山东未名生物医药股份有限公司 2023 年股票期权激励计划（草 案）》《公司章程》的规定，对公司 2023 年股票期权激励计划第二个行权期行 权条件未成就及注销部分股票期权事项进行审核，发表核查意见如下： 综上，监事会同意公司 2023 年股票期权激励计划第二个行权期行权条件未 成就及注销部分股票期权事项。 山东未名生物医药股份有限公司 监 事 会 2025 年 4 月 28 日 本次注销 2023 年股票期权激励计划授予的股票期权第二个行权期行权条件 未成就以及部分激励对象因个人原因离职不再具备激励资格的股票期权事宜，符 合《上市公司股权激励管理办法》等法律法规、规范性文件及公司《2023 年激 励计划》的规定，决策审批程序合法、合规，不存在损害公 ...

| 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 高宝林 | 7382.28 | 18.42 | 不变 | | 石庭波 | 883.13 | 2.20 | 不变 | | 陈寿丰 | 706.00 | 1.76 | 不变 | | 申万宏源证券（000562）有限公司 | 579.30 | 1.45 | -2.15 | | 朱燕珍 | 317.91 | 0.79 | -101.59 | | 蔡文彬 | 291.31 | 0.73 | 27.46 | | 中信建投（601066）证券股份有限公司 | 263.68 | 0.66 | -10.03 | | 南方中证1000ETF | 247.17 | 0.62 | -26.87 | | 陈豪 | 241.17 | 0.60 | 新进 | | 香港中央结算有限公司 | 237.85 | 0.59 | -176.06 | | 较上个报告期退出前十大股东有 | | | | | 杨晓东 | 447.00 | 1.12 | 退出 | 三、分红送配方案情况 本次公司不分配不转赠。 数据四舍五入 ...

浙江天册（深圳）律师事务所 关于 山东未名生物医药股份有限公司 2023 年股票期权激励计划 注销部分股票期权事项的 法律意见书 中国广东省深圳市南山区科发路 222 号康泰创新广场 34 楼 518057 电话：0755-83739000 传真：0755-26906383 致：山东未名生物医药股份有限公司 浙江天册（深圳）律师事务所（以下简称本所）受山东未名生物医药股份有 限公司（以下简称未名医药或公司）委托，担任公司实施 2023 年股票期权激励 计划（以下简称本次激励计划）的专项法律顾问。本所根据《中华人民共和国公 司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券 法》）、《上市公司股权激励管理办法》（以下简称《管理办法》）等法律、行 政法规、部门规章及其他规范性文件（以下合称法律法规）及《山东未名生物医 药股份有限公司章程》（以下简称《公司章程》）、《山东未名生物医药股份有 限公司 2023 年股票期权激励计划（草案）》（以下简称《激励计划（草案）》） 的有关规定，就未名医药本次激励计划注销部分股票期权（以下简称本次注销） 相关事项出具本法律意见书。 为出具本法律意见书，本所律师 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥35,329,856.70, a decrease of 57.84% compared to ¥83,804,783.29 in the same period last year[5] - The net loss attributable to shareholders was ¥36,850,397.17, representing a 33.01% increase from a loss of ¥27,704,081.15 in the previous year[5] - The net cash flow from operating activities was -¥58,614,130.67, a significant decline of 285.59% compared to -¥15,200,975.67 in the same period last year[5] - The basic and diluted earnings per share were both -¥0.0559, a decrease of 33.10% from -¥0.0420 in the previous year[5] - The company reported a 57.84% decrease in operating income primarily due to product recalls[13] - Total operating revenue for the current period is CNY 35,329,856.70, a decrease of 57.8% compared to CNY 83,804,783.29 in the previous period[28] - Net profit for the current period is a loss of CNY 49,818,616.89, compared to a loss of CNY 27,055,340.81 in the previous period, indicating a worsening financial performance[29] - The net profit attributable to the parent company was -36,850,397.17 yuan, compared to -27,704,081.15 yuan in the previous period, indicating a decline[30] - The total comprehensive income amounted to -49,818,616.89 yuan, compared to -27,055,340.81 yuan in the previous period[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,167,843,796.67, down 1.28% from ¥2,195,918,588.20 at the end of the previous year[5] - The balance of other receivables increased by 97.55% compared to the beginning of the year, mainly due to prepayments made for the industrial park[8] - The balance of contract liabilities increased by 160.57% compared to the beginning of the year, attributed to pre-received contract payments[10] - Total current assets decreased to CNY 729,876,009.75 from CNY 747,007,338.19, a decline of 2.3%[26] - Total liabilities increased to CNY 190,692,131.12 from CNY 173,612,003.09, an increase of 9.9%[27] - Long-term equity investments slightly decreased to CNY 1,048,822,473.33 from CNY 1,055,730,183.04, a decrease of 0.7%[26] Cash Flow - The company reported a decrease in cash and cash equivalents from RMB 506,403,730.00 at the beginning of the period to RMB 445,010,515.55 at the end of the period[25] - The company’s cash flow management remains a focus, with a significant reduction in cash reserves noted[25] - Cash inflows from operating activities totaled 67,021,948.27 yuan, down from 103,266,237.28 yuan in the previous period[32] - The net cash flow from operating activities was -58,614,130.67 yuan, compared to -15,200,975.67 yuan in the previous period[32] - The cash and cash equivalents at the end of the period were 442,764,542.95 yuan, down from 504,337,388.39 yuan at the beginning of the period[33] - The net cash increase in cash and cash equivalents was -61,572,845.44 yuan, compared to an increase of 63,453,004.06 yuan in the previous period[32] Expenses and Costs - Total operating costs for the current period amount to CNY 79,830,761.69, down 25.0% from CNY 106,361,412.35 in the previous period[29] - Research and development expenses for the current period were CNY 4,880,913.96, down 21.4% from CNY 6,208,293.77 in the previous period[29] - The company reported a financial cost of CNY -803,773.97, indicating a reduction in financial expenses compared to CNY -277,387.95 in the previous period[29] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 38,037[18] - The company’s top 10 unrestricted shareholders include Shenzhen Yilian Technology Co., Ltd. with 25,204,000 shares, accounting for 3.82%[19] - The company has not disclosed any changes in the participation of major shareholders in margin trading and securities lending activities[19] - The company has not identified any related party relationships or concerted actions among the top 10 shareholders[19] Corporate Actions and Agreements - The company approved a capital increase of RMB 290 million for its wholly-owned subsidiary, Shandong Yandu Biotechnology Co., Ltd., raising its registered capital to RMB 300 million[22] - The company signed a clinical trial technical service agreement for the Phase III clinical trial of recombinant human nerve growth factor eye drops with Tianjin Happy Life Technology Co., Ltd.[21] - The company plans to sign a general contracting agreement for the cleanroom and electromechanical project of the Shandong Weiming Biomedical Industrial Park with Shandong Zhongda Engineering Technology Co., Ltd.[23] - The company’s wholly-owned subsidiary will procure necessary systems and materials for the production workshop of recombinant human nerve growth factor eye drops from Jiangsu Suhao Innovation Technology Group Co., Ltd.[24] Compliance and Reporting - The company did not undergo an audit for the first quarter report[34] - The report was issued by the Board of Directors on April 28, 2025[35]

Core Viewpoint - Unimed Pharmaceutical's subsidiary, Tianjin Unimed, has been suspended from production and sales due to regulatory measures, significantly impacting the company's operations and revenue potential [2][3]. Group 1: Company Operations - Tianjin Unimed, primarily engaged in the production and sales of interferon drugs, generated revenue of 217 million yuan in 2024, accounting for 60.09% of Unimed Pharmaceutical's total revenue [2]. - The company's interferon business achieved revenue of 303 million yuan in 2023, representing 70.47% of total revenue, an increase from approximately 229 million yuan in 2022, which was 64.27% of total revenue [3]. - The main products contributing to Unimed's revenue are nerve growth factor and interferon products, which together account for over 90% of total revenue, with both categories having a gross margin close to 80% [2]. Group 2: Regulatory Issues - The suspension of Tianjin Unimed's production and sales is due to the interferon α2b spray being found non-compliant with biological activity standards, leading to procurement suspensions in multiple regions [2]. - The company must complete rectification and inspection to resume production, and products must meet national standards before being sold again [3]. - If the suspension lasts longer than three months, it may trigger additional risk warnings for the company [2].